An interventional study of Biopsy and Cytobrush in Covid19 and Olfactory Dysfunction, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 173 studies in COVID-19 with a site in Belgium — 11 open to participants now, 16 under way, 6 of them phase 3. COVID-19 · Belgium.
Among the 173 studies in COVID-19 with a site in Belgium, this one is the 37th largest by planned enrollment of the 103 interventional ones that give a count, is one of 4 that started in 2024, is one of 38 with no phase, reaches primary completion later than 6 of the 15 other live ones, and was the 168th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →11 of the 173 studies in COVID-19 with a site in Belgium are open now. Recruiting first, the newest first:
Pfizer · Sites in Belgium, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Belgium, United States, Argentina and 16 more countries
Ages 12+
Technical University of Munich · Sites in Belgium, Austria, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
AstraZeneca · Sites in Belgium, United States, Argentina and 36 more countries
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 25 · Phase 3 29 · Phase 4 6
First in 2016; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 150 across the 103 interventional studies, 230 across the 69 observational. Of the 133 that completed or were terminated, 36 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 173 have an industry lead sponsor. The 10 most frequent:
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Universitaire Ziekenhuizen KU Leuven has 8 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
6 of the studies in COVID-19 with a site in Belgium that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03188796Phase 3Medical University of GrazThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients | 2027-07 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06482138Universitaire Ziekenhuizen KU LeuvenDysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation | 2026-12-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 173 studies in COVID-19 with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigation of the mechanisms of persistent SARS-CoV-2 associated olfactory dysfunction (OD) in patients with well-documented olfactory function. The investigators plan to collect olfactory cleft biopsies and cytobrushes in COVID-19 patients and controls.
An explorative prospective clinical study using human body materials of living post-COVID-19 patients with and without OD, to study the mechanisms of persisting olfactory dysfunction. Patients consult ENT specialist for medical purposes and undergo standard-of-care diagnostics and management. The collected tissues from the olfactory cleft mucosa will be analyzed using single cell RNA sequencing and RNAscope combined with immunohistochemistry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biopsy and cytobrush during a scheduled structural intervention in general anesthesia
Procedure: Biopsy and Cytobrush
Biopsy and cytobrush during consultation in local anesthesia
Procedure: Biopsy and Cytobrush
Collection of olfactory cleft biopsies and cytobrushes
Analysis of olfactory cleft biopsies
Morphological and histomolecular differences between OD and control patients * Evaluating tissue pathology: * Metaplasia * hypertrophy * aberrant scar formation * apoptosis * presence of inflammatory cells \[H\&E, CD68 and CD3 stainings, RNAscope\] * Presence of SARS-CoV-2 RNA * Percentage of OSNs versus sustentacular cells; maturation of OSNs
Time frame: From enrollment of 1 patient until analyzed, 1 month
Analysis of olfactory cytobrushes
Morphological and histomolecular differences between OD and control patients * Evaluating tissue pathology: * Metaplasia * hypertrophy * aberrant scar formation * apoptosis * presence of inflammatory cells \[H\&E, CD68 and CD3 stainings, RNAscope\] * Presence of SARS-CoV-2 RNA * In the olfactory epithelium: percentage of OSNs versus sustentacular cells; maturation of OSNs
Time frame: From enrollment of 1 patient until analyzed, 1 month
Not enrolling at this site.
Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 35 months is above that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →